Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.57 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 4/20 | 0.36 |
| ▸ | JAK3 | P52333 | 3/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.33 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29858360 | 1.00 | APLNR (0.57) | APLNRESR1ESR2HDAC6JAK2 | |
| SCHEMBL25203689 | 1.00 | APLNR (0.57) | APLNRESR1ESR2HDAC6JAK2 | |
| SCHEMBL1856342 | 1.00 | APLNR (0.57) | APLNRESR1ESR2HDAC6JAK2 | |
| SCHEMBL3234164 | 0.85 | APLNR (0.52) | APLNRKCNH2FFAR2NR1I2MAPK1 | |
| SCHEMBL14815592 | 0.84 | APLNR (0.44) | APLNR | |
| SCHEMBL179299 | 0.82 | APLNR (0.51) | APLNRESR1ESR2HDAC6JAK2 | |
| SCHEMBL3234173 | 0.81 | APLNR (0.49) | APLNRESR1ESR2HDAC6HRH1 | |
| SCHEMBL22506484 | 0.80 | APLNR (0.64) | APLNRHDAC6JAK2JAK3KMT2A | |
| SCHEMBL20470117 | 0.80 | APLNR (0.64) | APLNRHDAC6JAK2JAK3KMT2A | |
| SCHEMBL20470327 | 0.80 | APLNR (0.64) | APLNRHDAC6JAK2JAK3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| WO-2025101892-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS AND USES THEREOF | Astellas Engineered Small Molecules US, Incorporated (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20240383902-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-11-21 | — | — | US | disclosed |
| WO-2024222860-A1 | SALT OF MORPHOLINE HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏豪森药业集团有限公司 | 2024-10-31 | — | — | WO | disclosed |
| CN-118852146-A | Crystal form of morpholine heterocyclic compound, and preparation method and application thereof | 江苏豪森药业集团有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118176185-A | 2- (Aryl-2-yl) morpholine and deuterated derivative thereof, preparation method and application | 上海翰森生物医药科技有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| US-11970498-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-04-30 | — | — | US | disclosed |
| US-11932648-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| EP-2069364-A1 | NOVEL 5, 7-DISUBSTITUTED [1, 3]THIAZOLO [4, 5-D]PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2009-06-17 | — | — | EP | disclosed |
| EP-2069365-A1 | NOVEL 5,7-DISUBSTITUTED [1, 3]THIAZOLO [4, 5D]PYRIMIDIN-2 (3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009016410-A2 | CHEMICAL COMPOUNDS 831 | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009007753-A2 | 4- (3-AMINOPYRAZOLE) -PYRIMIDINE DERIVATIVEE AND THEIR USE AS TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| WO-2008132502-A1 | PYRAZOLYL-AMINO-SUBSTITUTED PYRIMIDINES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008117050-A1 | PYRAZOLYL-AMINO-SUBSTITUTED PYRAZINES AND THEIR USE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008039139-A1 | NOVEL 5,7-DISUBSTITUTED [1, 3] THIAZOLO [4, 5] PYRIMIDIN-2 (3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039139-A1 | NOVEL 5,7-DISUBSTITUTED [1, 3] THIAZOLO [4, 5] PYRIMIDIN-2 (3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008039138-A1 | NOVEL 5, 7-DISUBSTITUTED [1, 3 ] THIAZOLO [4, 5-D] PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932648-B2 | CDK2 inhibitors | CDK2, CDK20, CDK2AP1 | APLNR 4664/4885ESR1 1428/4885ESR2 2253/4885 |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ABL1, FLT3, ERBB2 | APLNR 3478/4885ESR1 3445/4885ESR2 2264/4885 |
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | APLNR 3263/4885ESR1 1253/4885ESR2 1944/4885 |
| US-11970498-B2 | CDK2 inhibitors | CDK2, CDK20, CDK2AP1 | APLNR 4664/4885ESR1 1428/4885ESR2 2253/4885 |
| US-20240383902-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | APLNR 4664/4885ESR1 1428/4885ESR2 2253/4885 |
| US-12545684-B2 | CDK2 inhibitors | CDK2, CDK4, CDK1 | APLNR 4594/4885ESR1 1827/4885ESR2 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.